Your session is about to expire
← Back to Search
Anti-fibrinolytic agent
Topical and Intravenous TXA for Spinal Deformity
Phase < 1
Waitlist Available
Led By Firoz Miyanji, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 week visit
Awards & highlights
No Placebo-Only Group
Summary
Our study will evaluate the use of topical and intravenous (IV) Tranexamic Acid (TXA) in spine surgery. The purpose of TXA is to prevent clotting during surgery to reduce blood loss. When used intravenously, it has been shown to safe, efficacious, and effective in reducing transfusion requirements and blood loss in spine surgeries. We want to evaluate the effect of using TXA topically and intravenously to see if it further reduces blood loss in children undergoing major surgery compared to IV TXA only
Eligible Conditions
- Spinal Deformity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 week visit
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 week visit
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Complications (reporting)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Topical and Intravenous TXAExperimental Treatment2 Interventions
Group II: Intravenous TXA onlyActive Control1 Intervention
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,296 Total Patients Enrolled
Firoz Miyanji, MDPrincipal InvestigatorClinical Assistant Professor
Brett Kilb, MdStudy ChairResident
Share this study with friends
Copy Link
Messenger